Literature DB >> 8501486

Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group.

J D Rubin1, C Ferencz, C Loffredo.   

Abstract

We analyzed use of therapeutic drugs during pregnancy by 2752 mothers of infants without major congenital malformations. During pregnancy, 68% of the women used at least one prescription or non-prescription drug. Drug use in pregnancy was significantly more common for women who were white, older, married, better educated, of higher income and occupational status, receiving private prenatal care and not living in urban areas. Number of maternal illnesses, higher socioeconomic status, white race, multiparity and use of recreational drugs explained 26% of reported drug use. The mean number of drugs reported (1.2) underestimates total drug exposure due to exclusion of some drug categories including multivitamins and illicit drugs. Since the majority of women giving birth to normal infants report use of at least one pharmacologic agent during pregnancy, attribution of adverse outcome to drug use in an individual case is rarely justified.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501486     DOI: 10.1016/0895-4356(93)90132-k

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  17 in total

Review 1.  Effect of over-the-counter drugs on the unborn child: what is known and how should this influence prescribing?

Authors:  S Kacew
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008.

Authors:  Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Katherine E Kelley; Carol Louik; Sonia Hernández-Díaz
Journal:  Am J Obstet Gynecol       Date:  2011-04-22       Impact factor: 8.661

3.  Case-control analysis of maternal prenatal analgesic use and cardiovascular malformations: Baltimore-Washington Infant Study.

Authors:  Courtney A Marsh; Janet D Cragan; C J Alverson; Adolfo Correa
Journal:  Am J Obstet Gynecol       Date:  2014-03-27       Impact factor: 8.661

4.  Shared gene expression profiles in developing heart valves and osteoblast progenitor cells.

Authors:  Santanu Chakraborty; Jonathan Cheek; Bhuvaneswari Sakthivel; Bruce J Aronow; Katherine E Yutzey
Journal:  Physiol Genomics       Date:  2008-07-08       Impact factor: 3.107

5.  Predictors of the use of medications before and during pregnancy.

Authors:  Marina Odalovic; Sandra Vezmar Kovacevic; Hedvig Nordeng; Katarina Ilic; Ana Sabo; Ljiljana Tasic
Journal:  Int J Clin Pharm       Date:  2013-02-07

6.  Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women.

Authors:  Charlotte Olesen; Nana Thrane; Tine Brink Henriksen; Vera Ehrenstein; Jørn Olsen
Journal:  Eur J Clin Pharmacol       Date:  2006-05-04       Impact factor: 2.953

Review 7.  Prescription drug use during pregnancy in developed countries: a systematic review.

Authors:  Jamie R Daw; Gillian E Hanley; Devon L Greyson; Steven G Morgan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-07-20       Impact factor: 2.890

8.  Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.

Authors:  Margaret A Honein; Cynthia A Moore; J David Erickson
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy.

Authors:  Joshua J Gagne; Vittorio Maio; Vincenzo Berghella; Daniel Z Louis; Joseph S Gonnella
Journal:  Eur J Clin Pharmacol       Date:  2008-08-07       Impact factor: 2.953

10.  Use of antihistamine medications during early pregnancy and isolated major malformations.

Authors:  Suzanne M Gilboa; Matthew J Strickland; Andrew F Olshan; Martha M Werler; Adolfo Correa
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.